
This study investigates the safety and effectiveness of the glucagon-like peptide-1 receptor agonist dulaglutide in type 2 diabetes mellitus (T2DM) patients. In a real-world study across 46 hospitals, observations revealed treatment-emergent adverse events, glycated hemoglobin changes, and patient outcomes.
Like
Save
Share